ThinkEquity
http://www.thinkequity.comThinkEquity offers research, investment banking, wealth management, and asset management services for institutional and individual investors.
View Older Stories View More Recent Stories
-
Marpai, Inc. Announces Proposed Public Offering of Common Stock
-
ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION
-
G Medical Innovations Holdings Ltd. Announces Closing of Public Offering
-
G Medical Innovations Holdings Ltd. Announces Closing of Public Offering
-
TG Venture Acquisition Corp. Files Presentation About its Pending Business Combination with The Flexi Group, One of APAC's Largest Operators of Flexible Workspaces
-
G Medical Innovations Holdings (GMVD) Prices 12M Share Offering at $0.80/sh
-
G Medical Innovations Holdings Ltd. Announces Pricing of Public Offering
-
G Medical Innovations Holdings Ltd. Announces Pricing of Public Offering
-
Vivani Medical (VANI) Files for Proposed IPO of its Subsidiary Cortigent
-
Vivani Medical Announces Public Filing of Registration Statement for the Proposed Initial Public Offering of Cortigent, Inc., a Subsidiary Advancing the Business of its Neuromodulation Division
-
Azitra (AZTR) Announces 2.4M Share IPO at $5/sh
-
Cortigent (CRGT) Announces Proposed IPO
-
Form X-17A-5 THINKEQUITY LLC For: Dec 31
-
Think Equity: Society Pass (Nasdaq: SOPA) – Path to Profitability
-
Think Equity: Society Pass (Nasdaq: SOPA) - Path to Profitability
-
Think Equity: Society Pass (Nasdaq: SOPA) - Path to Profitability
-
Murchinson Issues Letter to Fellow Shareholders Encouraging Them to See Through Nano Dimension’s Deceptive Scare Tactics and Make Their Voices Heard
-
Beamr Imaging Ltd. Announces Closing of Initial Public Offering
-
Beamr Imaging Ltd. Announces Closing of Initial Public Offering
-
Beamr Imaging (BMR) Prices 1.95M Share IPO at $4/sh
-
Beamr Imaging Ltd. Announces Pricing of Initial Public Offering
-
Beamr Imaging Ltd. Announces Pricing of Initial Public Offering
-
KWESST Generates New Regional Opportunities at IDEX 2023
-
Tivic Health Systems, Inc. Announces Closing of Public Offering
-
Alliance Entertainment Completes Business Combination with Adara Acquisition Corp.
-
Blink Charging Announces Closing of Public Offering of Common Stock for Gross Proceeds of $100 Million
-
Tivic Health Systems (TIVC) prices 20m shares at $0.25
-
Tivic Health Systems, Inc. Announces Pricing of Public Offering
-
Lirum Therapeutics Announces Closing of $7 Million Private Placement of Common Stock
-
Lirum Therapeutics Announces Closing of $7 Million Private Placement of Common Stock
-
Blink Charging (BLNK) prices 8.33m shares at $12
-
Blink Charging Announces Pricing of its Upsized Public Offering of Common Stock
-
Society Pass (Nasdaq: SOPA) Engages ThinkEquity to Facilitate Stock Repurchase Program of Up to US$2 Million Commencing on 01 February 2023
-
Society Pass (Nasdaq: SOPA) Engages ThinkEquity to Facilitate Stock Repurchase Program of Up to US$2 Million Commencing on 01 February 2023
-
DCS Announces Launch of Initial Public Offering for Uplisting to NYSE American
-
1847 Holdings’ Subsidiary, 1847 Cabinets Inc., Engages ThinkEquity to Explore Strategic Alternatives
-
ProPhase Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
-
ProPhase Labs (PRPH) Acquires Rights to Novel Esophageal Cancer Test
-
ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test
-
Netcapital Inc. Announces Closing of Public Offering
-
Nexcella, Inc. in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloi
-
Nexcella, Inc. in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloi
-
Immix Biopharma (IMMX) in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma and AL Amyloidosis
-
Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amylo
-
Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amylo
-
Netcapital (NCPL) prices 1.247 million share offering at $1.40
-
Netcapital Inc. Announces Pricing of Public Offering
-
Netcapital (NCPL) Announces Proposed Public Offering of Common Stock
-
Netcapital Inc. Announces Proposed Public Offering of Common Stock
-
KWESST Micro Systems Inc. Announces Closing of Public Offerings for $14.1 Million in Aggregate Gross Proceeds

